The internal causes of Lianhua Qingwen in the treatment of new coronary pneumonia

According to the National Health Commission, as of 24:00 on September 22, there were 28 confirmed cases of new coronary pneumonia, including 20 in Fujian and 8 in Heilongjiang

Blending famous prescriptions of past generations, selected medicines have anti-inflammatory and anti-viral effects

The traditional Chinese medicine Lianhua Qingwen Capsules (granules) is a patented Chinese medicine developed by using the theory of collateral disease to explore the law and treatment of exogenous febrile disease and plague transmission.

Lianhua Qingwen has a good preventive effect on a variety of viral infectious diseases, which is achieved through overall regulation and multi-target effects

Scientific research evidence is full and clear, Lianhua Qingwen has a clear role in preventing and curing new crowns

Since the outbreak of the new crown pneumonia, many scientific research institutes and expert teams have carried out research on the prevention and treatment of new coronary pneumonia with the traditional Chinese medicine Lianhua Qingwen Capsules, and published many academic papers in international authoritative journals, providing support for Lianhua Qingwen's prevention and treatment of new coronary pneumonia.

The Guangzhou Institute of Respiratory Health and the State Key Laboratory of Respiratory Diseases published the paper "Lianhua Qingwen has antiviral and anti-inflammatory effects on the new coronavirus" in the mainstream journal of pharmacology, "Pharmacology Research", confirming that Lianhua Qingwen passed Inhibiting virus replication and inhibiting the expression of host cell inflammatory factors, thereby exerting anti-new coronavirus activity, provides experimental basis for the application of Lianhua Qingwen in the treatment of new coronary pneumonia

The "Prospective, randomized, controlled, multi-center clinical study of traditional Chinese medicine Lianhua Qingwen in the treatment of new coronavirus pneumonia" jointly participated by more than 20 new coronary pneumonia hospitals was published in the international plant medicine journal "Botanical Medicine" with a high impact factor On

Professor Wu Caisheng from the School of Pharmacy of Xiamen University and the team of Professor Chai Yifeng from the Naval Military Medical University found that among the components of Lianhua Qingwen measured in humans, rhein, forsythin A, forsythin I, neochlorogenic acid and its isomers May play a potential role in inhibiting the new coronavirus

Precisely because there is a large amount of accurate basic experimental and clinical research evidence, on April 12, 2020, the National Medical Products Administration approved Lianhua Qingwen Capsules (granules) to add new indications for the treatment of "new coronavirus pneumonia mild and common"

The latest research shows that whether it is Alpha, Beta mutant strains, or this time Delta (Delta strain), even Hua Qingwen has shown a stable in vitro antiviral effect

The anti-epidemic effect at home and abroad is remarkable, and Lianhua Qingwen is widely recognized

Lianhua Qingwen Capsules/granules, as one of the "three medicines and three prescriptions" selected for the treatment of new coronary pneumonia in Chinese medicine, has played an important therapeutic role

The effect of Lianhua Qingwen on the prevention and treatment of new coronary pneumonia has not only been widely confirmed in China, but also won unanimous praise overseas

Zimbabwe’s largest and most influential daily newspaper "Herald" senior editor Hatred Zenenga (Hatred Zenenga) in the newspaper in January, shared his experience after being diagnosed with the new crown

The second largest television station in the Philippines-GMA TV News Network reported in August 2020 the experience of Benjamin Abalos, the former Mayor of Mandaluyong City and the current Director of Metro Manila Development Agency, taking Lianhua Qingwen to treat new coronary pneumonia.

In Thailand, Indonesia, Russia, Cambodia and other countries, Lianhua Qingwen also entered the local designated hospitals for new coronary pneumonia to treat mild and ordinary patients

Since entering the market in 2003, Lianhua Qingwen has been recommended more than 20 times at the national level.